Sumatriptan for Migraine: How It Works, Evidence, and Safety

Sumatriptan is an acute, or abortive, migraine drug, meaning it is taken to stop an attack that has already begun. It does not lower how often attacks happen, and it is not taken every day as a preventive. People who have frequent migraines often pair an acute drug like sumatriptan with a separate preventive medicine that they take daily.

It was the first triptan, a class of drugs designed for migraine. The FDA approved sumatriptan as a subcutaneous injection under the brand name Imitrex in December 1992, then approved oral tablets in June 1995 and a nasal spray in 1997. The molecule is now an inexpensive generic. The injection works fastest and is used when an attack comes on hard or with heavy nausea; the tablet is the most common form; the nasal spray is an option for people who cannot keep a pill down.

Sumatriptan acts on serotonin receptors in and around the brain to switch off a migraine attack. It is a selective agonist at the 5-HT1B and 5-HT1D receptors, which means it binds to and activates these two receptor types and largely leaves others alone. Triptans target the migraine process at more than one point, which is the subject of our explainer on how triptans work.

Two actions matter. Through 5-HT1B receptors on blood vessels, sumatriptan constricts cranial vessels that have widened during an attack. Through 5-HT1D receptors on trigeminal nerve endings, it blocks the release of inflammatory neuropeptides, including calcitonin gene-related peptide (CGRP), that drive migraine pain. Together these interrupt the attack rather than just dull the pain.

The vessel-narrowing action is also the source of the drug's main safety concern. Sumatriptan does not narrow only the vessels around the brain, so it is avoided in people whose hearts or other arteries cannot tolerate any added constriction.

Sumatriptan reliably stops migraine attacks for a meaningful share of people, and the strongest summary of the evidence is a Cochrane review. The review pooled 61 studies in over 37,000 people and reported outcomes by dose and route (Derry 2012). For the oral tablet, the most useful numbers are the share of people who became completely pain-free at two hours, since that is the result patients care about most.

At the 100 mg oral dose, about 32% of people were pain-free at two hours, compared with 11% on placebo. At the 50 mg dose, about 28% were pain-free at two hours, again versus 11% on placebo. Headache relief, a looser measure counting people whose pain dropped from moderate or severe to mild or none, reached about 61% at 100 mg and 57% at 50 mg, versus 32% on placebo. The 100 mg dose worked somewhat better than 50 mg but caused more side effects.

Major guidelines reflect this evidence. The American Headache Society's 2021 consensus statement places triptans among the first-line options for treating moderate to severe migraine attacks, and for milder attacks that do not respond to simple pain relievers (Ailani 2021). Sumatriptan, as the oldest and best-studied triptan, anchors that recommendation.

Sumatriptan works best taken early in an attack, at mild pain, rather than after the headache has built. As an attack progresses, the nervous system becomes sensitized and the scalp and skin can turn tender, a state called allodynia. Once that sets in, triptans tend to work less well. Treating at the first sign of migraine pain gives the drug its best chance.

If the attack responds and then comes back, a second dose may be taken after two hours, as long as it stays within the daily maximum on the label. If the first dose does nothing at all, a second dose of the same drug usually will not help that attack, and waiting it out or switching approaches is the better move. The right limits depend on the form and dose, so follow the specific instructions for your prescription.

Most people tolerate sumatriptan, and the common side effects are mild and short-lived. Many people feel tingling, warmth, or flushing soon after a dose, sometimes called triptan sensations. A tight or heavy feeling in the chest, throat, or jaw is also common and is usually not coming from the heart, though it can be unsettling the first time. Dizziness and, with the injection, soreness at the injection site can also occur.

Serotonin syndrome, a rare reaction from too much serotonin activity, appears on the label as a risk when sumatriptan is combined with other serotonin-raising drugs such as some antidepressants. The real-world risk looks low and is debated, but it is worth telling your clinician about every medicine and supplement you take so the combination can be checked.

Using acute migraine drugs too often can backfire and cause medication-overuse headache, a pattern of rebound headaches that builds when these drugs are taken on roughly ten or more days a month. The fix is to cap how often the acute drug is used and, for frequent attacks, to add a preventive. Our guide to medication-overuse headache covers how this happens and how to step back from it.

Sumatriptan is not safe for everyone, mainly because narrowing blood vessels is dangerous for some hearts and arteries. The label rules it out for people with the following:

• Coronary artery disease, angina, or a history of heart attack
• Uncontrolled high blood pressure
• A history of stroke or transient ischemic attack
• Peripheral vascular disease, including reduced blood flow to the gut
• Hemiplegic migraine or migraine with brainstem aura, two rare types
• Use of an ergot drug or another triptan within the past 24 hours
• Use of a monoamine oxidase inhibitor (MAOI) within the past two weeks

This list is why sumatriptan needs a prescription and why a clinician screens for heart risk before starting it. Some of these are firm blocks; others depend on a person's full picture, which is the clinician's call.

Sumatriptan is the reference triptan, and most of the seven triptans work about as well as it does, with small differences in speed and strength. A large meta-analysis of oral triptans treated sumatriptan 100 mg as the benchmark and found that two drugs edged it out on the two-hour response (Ferrari 2001). Rizatriptan 10 mg showed better efficacy and more consistent results across attacks, and eletriptan 80 mg showed better efficacy but more side effects. We compare two of the most common choices in sumatriptan versus rizatriptan.

The differences are real but modest, and they do not change the safety picture. Every triptan acts on the same 5-HT1B/1D receptors and carries the same heart-related contraindications, so switching between them is about tolerability and speed, not about getting around the cautions. People also respond differently from one triptan to the next, so a drug that disappoints one person can work well for another, and trying a second triptan is reasonable when the first falls short.